[6-K] Polyrizon Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Polyrizon Ltd. furnished a Form 6-K that attaches a press release titled “Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation.”

The filing states that the first four paragraphs of this press release are incorporated by reference into the company’s Registration Statements on Form S-8, to be part of those registrations from the date this report is submitted, to the extent not superseded by later filings.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November 2025

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

5 Ha-Tidhar Street

Raanana, 4366507, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on November 6, 2025, titled “Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation.”

The first four paragraphs of the press release attached to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Polyrizon Ltd.
Date: November 6, 2025	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

2

FAQ

What did PLRZ file?

Polyrizon filed a Form 6-K furnishing a press release and related disclosures.

What is the topic of Polyrizon’s press release?

The title indicates reversible broad-spectrum viral blocking by an intranasal barrier-forming formulation.

Which documents incorporate the press release content by reference?

The first four paragraphs are incorporated into Polyrizon’s Form S-8 registration statements, effective upon submission, unless later superseded.

When was the press release issued?

The press release was issued on November 6, 2025.

Does this 6-K include detailed financial results?

No financial tables or earnings data are included in the provided content.

Where is Polyrizon headquartered?

The address listed is 5 Ha-Tidhar Street, Raanana, Israel.